- $18.55m
- -$50.77m
- $6.44m
NASDAQ RESUMED AT 01:28 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:23 PM
Kyntra Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kyntra Bio swings to profit in Q2 on deconsolidation of subsidiary
Brief: Kyntra Bio Inc Q2 Net Income From Cont Ops USD 11.974 Million
Kyntra Bio, Inc. expected to post a loss of $3.18 a share - Earnings Preview
Kyntra Bio, Inc. expected to post a loss of $3.18 a share - Earnings Preview
Brief: Kyntra Bio Presents New Roxadustat Data On Improvements In Patients With Anemia Due To Lower-Risk Myelodysplastic Syndromes
Kyntra Bio Q1 net loss narrows as revenue rises
Brief: Fibrogen Rebrands To Kyntra Bio
Brief: Roxadustat Granted Orphan Drug Designation For The Treatment Of Myelodysplastic Syndromes By The U.S. FDA
FibroGen posts Q3 net income of $200.6 mln after sale of China operations
Brief: Fibrogen Inc - Receives $6.4 Million Payment From Astrazeneca Treasury Limited - SEC Filing
FibroGen rises after company begins mid-stage study for prostate cancer therapy
Brief: FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
Brief: FibroGen Announces Approval Of Sale Of Fibrogen China To Astrazeneca By The China State Administration For Market Regulation
FibroGen Inc reports results for the quarter ended June 30 - Earnings Summary
FibroGen Inc expected to post a loss of $2.31 a share - Earnings Preview
Brief: FibroGen Announces Positive Type C Meeting With The FDA For Roxadustat In Patients With Anemia Associated With Lower-Risk Myelodysplastic Syndromes